as soon as is submitted to ZB.
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
Pharmacogenet. Genomics 27, 135-142 (2017)
Objective Inhibition of the renal sodium-glucose cotransporter 2 (SGLT2) is a novel concept in the therapy of diabetes mellitus. In this study, we first assessed whether common single nucleotide polymorphisms (SNPs) in the SGLT2-encoding gene SLC5A2 affect diabetes-related metabolic traits in subjects at risk for type 2 diabetes and, second, whether these have pharmacogenetic relevance by interfering with the response to empagliflozin treatment in patients with type 2 diabetes. Patients and methods Samples from a metabolically well-phenotyped cross-sectional study population (total N=2600) at increased risk for type 2 diabetes and pooled pharmacogenetic samples from patients from four phase III trials of empagliflozin (in total: 603 receiving empagliflozin, 305 receiving placebo) were genotyped for five common SNPs (minor allele frequencies >= 5%) present in the SLC5A2 gene locus. Results In the cross-sectional study, none of the SLC5A2 SNPs significantly influenced metabolic traits such as body fat, insulin sensitivity/resistance, insulin release, HbA(1c), plasma glucose, or systolic blood pressure when multiple testing was taken into account (all P >= 0.0083). Further, no relevant effect on response to treatment with empagliflozin on HbA(1c), fasting glucose, weight, or systolic blood pressure was observed for the SNPs tested in the pharmacogenetic study. Conclusion Common genetic variants in the SLC5A2 gene neither affects diabetes-related metabolic traits nor have a clinically relevant impact on response to treatment with the SGLT2 inhibitor empagliflozin.
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Genetic Polymorphism ; Genetic Predisposition ; Sodium-glucose Cotransporter 2 ; Type 2 Diabetes; Familial Renal Glucosuria; Placebo-controlled Trial; Double-blind; Add-on; Insulin Sensitivity; Sglt2 Inhibition; Type-2; Metformin; 24-week; Pharmacogenetics